Entera Bio’s (ENTX) “Buy” Rating Reiterated at HC Wainwright

Entera Bio (NASDAQ:ENTX)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a research report issued on Monday,Benzinga reports. They presently have a $10.00 price target on the stock.

A number of other research analysts have also recently weighed in on the stock. Wall Street Zen upgraded shares of Entera Bio to a “sell” rating in a report on Saturday, December 27th. Weiss Ratings restated a “sell (d-)” rating on shares of Entera Bio in a research note on Thursday, January 22nd. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $10.00.

Entera Bio Stock Down 11.1%

ENTX opened at $1.04 on Monday. Entera Bio has a 52 week low of $1.00 and a 52 week high of $3.22. The business has a fifty day simple moving average of $1.74 and a 200-day simple moving average of $2.04. The firm has a market cap of $47.69 million, a P/E ratio of -4.16 and a beta of 1.84.

Entera Bio (NASDAQ:ENTX) last posted its earnings results on Friday, November 14th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.02. Sell-side analysts expect that Entera Bio will post -0.28 earnings per share for the current year.

Hedge Funds Weigh In On Entera Bio

A number of institutional investors and hedge funds have recently modified their holdings of the company. HighTower Advisors LLC increased its holdings in Entera Bio by 137.8% in the fourth quarter. HighTower Advisors LLC now owns 43,140 shares of the company’s stock valued at $84,000 after buying an additional 25,000 shares during the last quarter. Citadel Advisors LLC boosted its position in shares of Entera Bio by 243.0% during the 3rd quarter. Citadel Advisors LLC now owns 39,978 shares of the company’s stock worth $77,000 after acquiring an additional 28,322 shares in the last quarter. Finally, Bessemer Group Inc. purchased a new position in shares of Entera Bio in the 2nd quarter valued at about $268,000. Institutional investors and hedge funds own 14.11% of the company’s stock.

Entera Bio Company Profile

Entera Bio, Inc is a clinical‐stage biopharmaceutical company pioneering the development of orally delivered peptide therapeutics. Utilizing its proprietary oral delivery platform, Entera Bio seeks to overcome the challenges of gastrointestinal absorption for large peptide molecules. The technology is designed to facilitate transit across the intestinal epithelium while preserving peptide structure and bioactivity, offering the potential for daily oral dosing in lieu of injectable formulations.

The company’s lead candidate, EB613, is an oral parathyroid hormone (PTH) analog under investigation for the treatment of osteoporosis.